Fund in honor of Rebecca Aleck Koltun

Dr. Kristen Spencer, MD

Claim this profile

Rutgers Cancer Institute of New Jersey

Studies Skin Cancer
Studies Cancer
14 reported clinical trials
46 drugs studied

Area of expertise

1Skin Cancer
Kristen Spencer, MD has run 7 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
Stage III
2Cancer
Kristen Spencer, MD has run 7 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
KRAS positive

Affiliated Hospitals

Image of trial facility.
Rutgers Cancer Institute Of New Jersey
Image of trial facility.
Laura And Isaac Perlmutter Cancer Center At NYU Langone

Clinical Trials Kristen Spencer, MD is currently running

Image of trial facility.

Avutometinib + Defactinib + Chemotherapy

for Pancreatic Cancer

This trial tests a new treatment combining two experimental drugs with two existing treatments for patients with newly diagnosed pancreatic cancer. The goal is to see if this combination can safely and effectively stop cancer growth and kill cancer cells. The study focuses on patients who have not yet received any treatment. One of the existing treatments used in the trial has been important in pancreatic cancer treatment but offers only modest improvements in symptoms and survival.
Recruiting1 award Phase 1 & 27 criteria
Image of trial facility.

CA-4948 + Chemotherapy

for Pancreatic Cancer

This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). CA-4948 is in a class of medications called kinase inhibitors. It works by blocking the action of abnormal proteins called interleukin-1 receptor-associated kinase 4 (IRAK4) and FMS-like tyrosine kinase 3 (FLT3) that signal cells to multiply. This may help keep cancer cells from growing. The usual approach for patients with pancreatic ductal adenocarcinoma is treatment with chemotherapy drugs gemcitabine and nab-paclitaxel. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill cancer cells. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Giving CA-4948 in combination with gemcitabine and nab-paclitaxel may shrink or stabilize metastatic or unresectable pancreatic ductal adenocarcinoma.
Recruiting1 award Phase 120 criteria

More about Kristen Spencer, MD

Clinical Trial Related2 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Kristen Spencer, MD has experience with
  • Atezolizumab
  • Panitumumab
  • Sotorasib
  • Nab-paclitaxel
  • Nivolumab
  • Oxaliplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kristen Spencer, MD specialize in?
Kristen Spencer, MD focuses on Skin Cancer and Cancer. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Kristen Spencer, MD currently recruiting for clinical trials?
Yes, Kristen Spencer, MD is currently recruiting for 5 clinical trials in New Brunswick New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Kristen Spencer, MD has studied deeply?
Yes, Kristen Spencer, MD has studied treatments such as Atezolizumab, Panitumumab, Sotorasib.
What is the best way to schedule an appointment with Kristen Spencer, MD?
Apply for one of the trials that Kristen Spencer, MD is conducting.
What is the office address of Kristen Spencer, MD?
The office of Kristen Spencer, MD is located at: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903 United States. This is the address for their practice at the Rutgers Cancer Institute of New Jersey.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.